$102.71
2.76% day before yesterday
NYSE, Apr 11, 10:10 pm CET
ISIN
US00846U1016
Symbol
A
Sector
Industry

Agilent Technologies Stock price

$102.71
-18.32 15.14% 1M
-41.11 28.58% 6M
-31.63 23.54% YTD
-42.29 29.17% 1Y
-28.55 21.75% 3Y
+26.50 34.77% 5Y
+59.67 138.64% 10Y
NYSE, Closing price Fri, Apr 11 2025
+2.76 2.76%
ISIN
US00846U1016
Symbol
A
Sector
Industry

Key metrics

Market capitalization $29.28b
Enterprise Value $31.18b
P/E (TTM) P/E ratio 23.60
EV/FCF (TTM) EV/FCF 23.76
EV/Sales (TTM) EV/Sales 4.77
P/S ratio (TTM) P/S ratio 4.48
P/B ratio (TTM) P/B ratio 4.86
Dividend yield 0.92%
Last dividend (FY24) $0.94
Revenue growth (TTM) Revenue growth -3.00%
Revenue (TTM) Revenue $6.53b
EBIT (operating result TTM) EBIT $1.59b
Free Cash Flow (TTM) Free Cash Flow $1.31b
Cash position $1.47b
EPS (TTM) EPS $4.35
P/E forward 20.22
P/S forward 4.35
EV/Sales forward 4.63
Short interest 1.56%
Show more

Is Agilent Technologies a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Agilent Technologies Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Agilent Technologies forecast:

10x Buy
48%
11x Hold
52%

Analyst Opinions

21 Analysts have issued a Agilent Technologies forecast:

Buy
48%
Hold
52%

Financial data from Agilent Technologies

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
6,533 6,533
3% 3%
100%
- Direct Costs 2,983 2,983
3% 3%
46%
3,550 3,550
3% 3%
54%
- Selling and Administrative Expenses 1,254 1,254
5% 5%
19%
- Research and Development Expense 439 439
8% 8%
7%
1,857 1,857
1% 1%
28%
- Depreciation and Amortization 267 267
0% 0%
4%
EBIT (Operating Income) EBIT 1,590 1,590
1% 1%
24%
Net Profit 1,259 1,259
2% 2%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Agilent Technologies directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agilent Technologies Stock News

Positive
Seeking Alpha
10 days ago
Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data s...
Neutral
Business Wire
20 days ago
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTC...
Neutral
Business Wire
24 days ago
SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology...
More Agilent Technologies News

Company Profile

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Head office United States
CEO Padraig Mcdonnell
Employees 17,900
Founded 1999
Website www.agilent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today